Deferoxamine mesylate
别名: Ba 33112, Desferrioxamine B, DFOM, NSC 644468, DFO 中文名称：甲磺酸去铁胺
Deferoxamine mesylate是Deferoxamine的甲磺酸盐，它可形成铁络合物并用作螯合剂。Deferoxamine 是一种铁死亡的抑制剂，可在体外低氧和高血糖状态下稳定 HIF-1α 的表达并改善HIF-1α的活性。Deferoxamine 可降低 beta-amyloid (Aβ) 的沉积并诱导自噬。请不要用生理盐水或者PBS配制储存液，可能会产生沉淀。
Deferoxamine mesylate Chemical Structure
CAS: 138-14-7
产品质控
批次：
纯度：
99.91%
99.91
常与Deferoxamine mesylate一起在实验中被使用的化合物
Deferoxamine mesylate可以逆转EMFF中颗粒细胞的细胞增殖活性，但不能逆转Z-VAD-FMK。
Deferoxamine mesylate和Ferrostatin-1可以逆转EMFF中颗粒细胞的细胞增殖活性。
Deferoxamine mesylate可以逆转EMFF中颗粒细胞的细胞增殖活性，但不能逆转Necrostatin-1。
Deferoxamine mesylate相关产品
| 相关产品 | Fer-1 (Ferrostatin-1) Erastin RSL3 Liproxstatin-1 FIN56 IKE(Imidazole ketone erastin) UAMC-3203 iFSP1 SRS16-86 SRS11-92 | 点击展开 |
|---|---|---|
| 相关化合物库 | 激酶抑制剂库 FDA药物库 天然产物库 已知活性药物库-I 高选择性抑制剂库 | 点击展开 |
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| HT-29 | Cell cycle assay | 10 uM | 24 hrs | Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 10 uM after 24 hrs | 20353152 |
| HT-29 | Cell cycle assay | 5 uM | 24 hrs | Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 5 uM after 24 hrs | 20353152 |
| HeLa | Bacteriostatic assay | >100 uM | 1 hr | Bacteriostatic activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as growth inhibition compound treated at >100 uM for 1 hr prior infection measured 24 hrs post infection by microscopy | 25027937 |
| SK-N-BE(2)-M17 | Cytoprotection assay | 1 mM | 2 hrs | Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by LDH assay | 28285915 |
| SK-N-BE(2)-M17 | Cytoprotection assay | 1 mM | 2 hrs | Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by LDH assay | 28285915 |
| SK-N-BE(2)-M17 | Cytoprotection assay | 1 mM | 2 hrs | Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by MTT assay | 28285915 |
| SK-N-BE(2)-M17 | Cytoprotection assay | 1 mM | 2 hrs | Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by MTT assay | 28285915 |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 4.51 μM. | 17602603 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 5 μM. | 19601577 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 7.35 μM. | 19216562 | |
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity at human A549 cells after 72 hrs by MTT assay, IC50 = 7.5 μM. | 22861499 | |
| SK-N-MC | Antiproliferative assay | 96 hrs | Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay, IC50 = 8.58 μM. | 17064069 | |
| SK-N-MC | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 9.89 μM. | 20303768 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 10 μM. | 22861499 | |
| DMS53 | Antiproliferative assay | 72 hrs | Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay, IC50 = 10 μM. | 22861499 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 12.5 μM. | 22858101 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 16.81 μM. | 28841514 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM. | 21055950 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM. | 22172311 | |
| U2OS | Function assay | 30 mins | Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay, EC50 = 17.8 μM. | 22172704 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay, IC50 = 21.63 μM. | 23312948 | |
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay, IC50 = 22.7 μM. | 21846118 | |
| SK-N-MC | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 22.7 μM. | 23276209 | |
| HT29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT29 cells after 72 hrs by MTS assay, IC50 = 36.1 μM. | 18345610 | |
| HCT116 | Function assay | 24 hrs | Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3 | 24900837 | |
| MDCK | Toxicity assay | Toxicity in MDCK cells by MTT method, IC50 = 9.49 μM. | 20041672 | ||
| SK-MN-C | Antiproliferative assay | Antiproliferative activity against human SK-MN-C cells by MTT assay, IC50 = 12.05 μM. | 18159922 | ||
| SK-N-MC | Antiproliferative assay | Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50 = 14.22 μM. | 17963372 | ||
| SK-N-MC | Toxicity assay | Toxicity in human SK-N-MC cells by MTT method, IC50 = 16.04 μM. | 20041672 | ||
| HL60 | Cytotoxicity assay | Cytotoxicity against human HL60 cells by alamar blue assay, GI50 = 18.4 μM. | 23266185 | ||
| SK-N-MC | Antiproliferative assay | Antiproliferative activity against human SK-N-MC cells, IC50 = 22 μM. | 19601577 | ||
| K562 | Cytotoxicity assay | Cytotoxicity against human K562 cells, GI50 = 33.1 μM. | 23266185 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Deferoxamine mesylate是Deferoxamine的甲磺酸盐，它可形成铁络合物并用作螯合剂。Deferoxamine 是一种铁死亡的抑制剂，可在体外低氧和高血糖状态下稳定 HIF-1α 的表达并改善HIF-1α的活性。Deferoxamine 可降低 beta-amyloid (Aβ) 的沉积并诱导自噬。请不要用生理盐水或者PBS配制储存液，可能会产生沉淀。 | |||
|---|---|---|---|---|
| 靶点 |
|
化学信息&溶解度
| 分子量 | 656.79 | 分子式 | C26H52N6O11S |
| CAS号 | 138-14-7 | SDF | -- |
| 储存条件(自收到货起) | 3年 -20°C 粉状 | ||
|
体外溶解度 |
DMSO : 100 mg/mL ( (152.25 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : 100 mg/mL (152.25 mM) Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Deferoxamine mesylate | Deferoxamine mesylate supplier | purchase Deferoxamine mesylate | Deferoxamine mesylate cost | Deferoxamine mesylate manufacturer | order Deferoxamine mesylate | Deferoxamine mesylate distributor
